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Background: The degree of interlobar emphysema heterogeneity is thought to play an important 
role in the outcome of endoscopic lung volume reduction (ELVR) therapy of patients with 
advanced COPD. There are multiple ways one could possibly define interlobar emphysema 
heterogeneity, and there is no standardized definition.
Purpose: The aim of this study was to derive a formula for calculating an interlobar emphy-
sema heterogeneity index (HI) when evaluating a patient for ELVR. Furthermore, an attempt 
was made to identify a threshold for relevant interlobar emphysema heterogeneity with regard 
to ELVR.
Patients and methods: We retrospectively analyzed 50 patients who had undergone techni-
cally successful ELVR with placement of one-way valves at our institution and had received lung 
function tests and computed tomography scans before and after treatment. Predictive accuracy 
of the different methods for HI calculation was assessed with receiver-operating characteristic 
curve analysis, assuming a minimum difference in forced expiratory volume in 1 second of 
100 mL to indicate a clinically important change.
Results: The HI defined as emphysema score of the targeted lobe (TL) minus emphysema score 
of the ipsilateral nontargeted lobe disregarding the middle lobe yielded the best predicative accu-
racy (AUC =0.73, P=0.008). The HI defined as emphysema score of the TL minus emphysema 
score of the lung without the TL showed a similarly good predictive accuracy (AUC =0.72, 
P=0.009). Subgroup analysis suggests that the impact of interlobar emphysema heterogeneity 
is of greater importance in patients with upper lobe predominant emphysema than in patients 
with lower lobe predominant emphysema.
Conclusion: This study reveals the most appropriate ways of calculating an interlobar emphy-
sema heterogeneity with regard to ELVR.
Keywords: CT-quantitative, COPD, emphysema heterogeneity, endoscopic lung volume 
reduction
Introduction
In recent years, more and more insight has been gained into endoscopic lung volume 
reduction (ELVR) as a treatment option for patients with severe COPD and con-
comitant emphysema.1–10 Several criteria for identifying patients who might benefit 
from ELVR and the lung lobe to be treated to achieve the best outcome have been 
proposed. An important criterion is interlobar emphysema heterogeneity.1,11,12 Put 
simply, the impact of interlobar emphysema heterogeneity on the outcome of ELVR 
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can be summed up as follows: if the lung lobes differ in the 
amount of emphysema, that is, the amount of damaged lung 
parenchyma, and the most afflicted lung lobe is eliminated 
with ELVR by inducing atelectasis, outcome is better than 
if the entire lung is affected equally and one lobe is removed 
by ELVR. While many studies found a significant impact 
of interlobar emphysema heterogeneity on outcome after 
ELVR, others did not.13
There are many different ways one could possibly define 
interlobar emphysema heterogeneity, and a standardized 
definition does not exist. In the VENT trial, the “percentage 
of heterogeneity was defined as the difference in quantitative 
emphysema score between the targeted lobe and the ipsilat-
eral adjacent nontargeted lobe” disregarding the middle lobe.1 
On the other hand, Valipour et al, for example, defined the 
interlobar heterogeneity index (HI) as the tissue destruction 
of the targeted lobe (TL) divided by the tissue destruction 
of the ipsilateral nontargeted (INTL) lobe, disregarding the 
middle lobe and lingual.14
The aim of this study was to find a definition of HI that 
best predicts the outcome of ELVR. To that end, we deter-
mined the HI in six different ways that we found theoretically 
reasonable with regard to ELVR and compared the results 
with the improvement of the forced expiratory volume in 
1 second (FEV
1
) after ELVR by performing a receiver-
operating characteristic (ROC) analysis.
We focused on FEV
1
 as the output parameter, for it seems 
to be the only output parameter that emphysema heterogene-
ity has a relevant impact on as shown in the study recently 
published by Thomsen et al.12 Nevertheless, other output 
parameters such as the residual volume (RV), the St George’s 
Respiratory Questionnaire (SGRQ) and the 6-minute walk 
test (6MWT) were briefly analyzed, too, using the same 
statistical method.
Patients and methods
The study was approved by the ethics committee of the 
Charité (EA1/213/16). It was a retrospective study from 
medical records. All patients were anonymized prior to data 
analysis. Based on the votum of the local ethic committee, 
informed consent forms were not required for this study.
Patient population
We retrospectively analyzed 62 patients who underwent 
ELVR with placement of one-way silicone Zephyr valves 
(Pulmonx, Redwood City, CA, USA) at our institution and 
had received lung function tests and computed tomography 
(CT) scans acquired in inspiration before and after ELVR. 
All patients had advanced COPD with a FEV
1
 between 15% 
and 45% of the predicted value, a RV of at least 150% of 
the predicted value and a total lung capacity of .100% at 
baseline after reversibility testing. Most patients completed 
the SGRQ and the 6MWT before and after treatment. All 
patients had been nonsmokers for at least 3 months at the 
time of treatment, as proven by serum carboxyhemoglobin 
levels of ,2%. The TL for ELVR was selected on the basis 
of visually estimated degree of emphysema, perfusion, 
and the absence of collateral ventilation determined by the 
Chartis system (Pulmonx) as described in the literature.15,16 
All patients underwent ELVR with an entire lobe treated as 
recommended by previous studies.3,17 Out of the 62 patients 
analyzed in this study, 24 patients showed a tendency toward 
upper lobe predominant emphysema in visual assessment 
and received upper lobe treatment while 38 patients showed 
a tendency toward lower lobe predominant emphysema and 
received lower lobe treatment.
As described in the literature, a TL volume reduc-
tion of .350 mL was considered a technically successful 
treatment.18 Out of the 62 evaluated patients, 12 did not meet 
this criterion and were therefore excluded, leaving 50 patients 
for the final analysis. Descriptive statistics of these 50 patients 
are summarized in Table 1.
high-resolution computed tomography 
with quantitative analysis
All patients underwent a CT scan (Light Speed Ultra 8, 
General Electric, Boston, MA, USA) for target lobe  selection 
and emphysema evaluation at baseline and for follow-up 
around 3 months after endoscopic valve implantation. The 
CT protocol was identical for all scans and included a slice 
thickness of 1.25 mm, 120 kVp, and 100 mAs. The scans 
were obtained in deep inspiration without intravenous 
contrast medium administration. We retrospectively per-
formed quantitative analysis of the chest CT scans using 
the MeVisPULMO 3D software, version 3.42 (Fraunhofer 
Table 1 Descriptive statistics of the study population (n=50)
Parameter Minimum Maximum Mean SD
lung volume in ml 4,488 10,122 6,870 1,338
Targeted lobe volume 
in ml
934 2,758 1,732 405
emphysema score of the 
lung in %
14 52 30 9
emphysema score of the 
targeted lobe in %
17 63 38 12
Volume difference of 
the targeted lobe 
after elVr in ml
−2,341 −362 −1,261 502
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Calculating an interlobar emphysema heterogeneity index
MEVIS, Bremen, Germany), which enables quantification 
of emphysematous lung parenchyma by determining the 
emphysema score defined as the ratio of voxels with a density 
below a certain threshold to the total number of voxels in 
the region of interest.19 We chose a threshold of −950 HU as 
proposed in previous studies.20–22 Furthermore, we used the 
software for semiautomatic segmentation of the lung into the 
lung lobes (left upper lobe, left lower lobe, right upper lobe, 
right middle lobe, and right lower lobe) as described in the 
literature.19,23 See also example in Figure 1.
heterogeneity index
The HI was calculated from the emphysema scores of the lung 
lobes determined from CT scans acquired in inspiration. We 
used six different methods for calculating the HI based on defi-
nitions found in the literature and those we found theoretically 
feasible with regard to ELVR.1,14 The methods to calculate the 
HI differ in whether only the ipsilateral half of the lung or the 
entire lung is taken into account, whether the middle lobe of 
the right half of the lung is neglected or not, and whether the 
emphysema scores of the respective lung lobes are subtracted 
from each other or divided by each other. The exact definitions 
and main characteristics of the HIs used and compared in this 
analysis are summarized in Tables 2 and 3.
In addition to that, there are other approaches to the 
HI like emphysema scores weighted for volume and HIs 
calculated from the tissue to air ratio. The latter version has 
been frequently used in bronchoscopic thermal vapor ablation 
trials.24–26 In this study, both these approaches have been 
assessed separately in addition to the aforementioned HIs. 
The respective analyses are shown in Tables S1–S3.
statistical analysis
Predictive accuracy of the six different HIs was assessed 
by ROC curve analysis, assuming a minimum difference in 
FEV
1
 of 100 mL to indicate a minimal clinically important 
difference (MCID), as proposed in the literature.27–30 In addi-
tion to that, other output parameters such as RV, 6MWT, and 
SGRQ were assessed with the same method using a MCID 
of 0. 31 L, 26 m, and 4 units, respectively, as suggested in 
the literature.29,30
The critical value was determined by the point on the 
ROC curve with the shortest distance to the upper left 
corner, that is, 100% sensitivity and 100% specificity.31 This 
distance (D) was calculated using the following formula: 
D = √([1 − sensitivity]2 + [1 − specificity]2). In order to test 
for statistically significant differences, pairs of heterogeneity 
scores were compared using DeLong’s test for two correlated 
ROC curves. ROC analysis was performed using IBM SPSS 
Statistics 19.0.0 (IBM Corporation, Armonk, NY, USA) 
and R version 3.3.0 with the package “pROC” version 1.8. 
A P-value ,0.05 was considered statistically significant.
Results
Of the 62 patients who had undergone ELVR at our insti-
tution and had received lung function tests and CT scans 
before and after ELVR, 50 showed a reduction in TL volume 
of .350 mL. Out of these 50 patients, 32 showed an increase 
Table 2 Definitions of the six interlobar emphysema hetero­




hI 1 Tl emphysema score/emphysema score of the 
InTl, excluding middle lobe
hI 2 Tl emphysema score/emphysema score of the 
InTl, including middle lobe
hI 3 Tl emphysema score/emphysema score of the 
whole lung without Tl
hI 4 Tl emphysema score – emphysema score of the 
InTl, excluding the middle lobe
hI 5 Tl emphysema score – emphysema score of the 
InTl, including the middle lobe
hI 6 Tl emphysema score – emphysema score of the 
whole lung without Tl
Note: emphysema score = ratio of the number of voxels with an attenuation 
,950 hU to the total number of voxels in the region of interest.
Abbreviations: hI, heterogeneity index; InTl, ipsilateral nontargeted lobe; Tl, 
targeted lobe.
Figure 1 Coronary 3D surface view of a processed hrCT scan of the lung acquired 
in inspiration depicting the lung lobes (semitransparent green, lower lobes; semi-
transparent red, upper lobe; semitransparent blue, right middle lobe) and voxels 
with a density below −950 hU (orange).
Note: The calculated emphysema scores, that is, percentages of voxels 
below −950 hU in a lung lobe to the total number of voxels in that lobe, were as 
follows: right upper lobe 26.4%, right middle lobe 16.0%, right lower lobe 14.9%, 
left upper lobe 27.8%, and left lower lobe 4.9%.
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 of more than 100 mL after ELVR, that is, had a 
difference classified as clinically relevant, and 18 did not. In 
the ROC analysis, most of the six emphysema HIs investi-
gated in this study showed statistically significant discrimina-
tory capacity between clinically successful treatment, that is, 
an increase in FEV
1
 of .100 mL, and clinically unsuccessful 
treatment, that is, an increase in FEV
1
 of ,100 mL (Table 4). 
HI 4, which is defined as emphysema score of the TL minus 
emphysema score of the INTL disregarding the middle lobe, 
yielded the best predicative accuracy (AUC =0.73, P=0.008). 
HI 6, which is defined as emphysema score of the TL minus 
emphysema score of the lung without the TL, showed a 
similarly good predictive accuracy (AUC =0.72, P=0.009). 
More generally speaking, the ROC analysis indicates that 
subtracting the percentages of emphysematous lung volume 
of the lobes in question yields a better predictive accuracy 
than dividing them. However, DeLong’s test showed no 
statistically significant differences between the ROC curves 
of HI 4 and HI 6 (P=0.543). The DeLong’s test did show 
statistically significant differences between the ROC curves 
of HI 1 and HI 2 (P=0.038), between the ROC curves of HI 
2 and HI 4 (P=0.048), and HI 4 and HI 5 (P=0.015).
The critical value that can be considered to indicate rel-
evant emphysema heterogeneity with regard to ELVR for the 
sensitivity and specificity level specified in Table 5 is ~9.47% 
for HI 6 and ~16.55% for HI 4 (Table 5 and Figure 2). The 
critical value of HI 6=9.47 yielded similarly good sensitiv-
ity and specificity with a 0.66 and 0.78, respectively. The 
critical value of HI 4=16.55% may be better when striving 
for higher specificity (specificity =0.89) at the cost of lower 
sensitivity (sensitivity =0.47).
Interestingly enough, in subgroup analysis of the patients 
with a tendency toward upper lobe predominant emphysema 
and upper lobe treatment HI 3, HI 4, HI 5, and HI 6 showed 
a statistically significant discriminatory capacity between 
clinically successful and unsuccessful treatment assessed by 
FEV
1
 increase and yielded better predictive accuracies than 
the analysis of the entire patient population with areas under 
the curve ranging from 0.82 to 0.88 (Table 6 and Figure 3). 
On the other hand, in subgroup analysis of patients with a 
tendency toward lower lobe predominant emphysema and 
lower lobe treatment, none of the HIs showed a statistically 
significant discriminatory capacity between clinically suc-
cessful and unsuccessful treatment assessed in FEV
1
 increase 
(Table 7 and Figure 4).
In Table S4, we also show the results of the ROC 
analysis of all 62 patients; these results are similar yet 
slightly less compelling than the above-described analysis 












hI 1 + − + − + −
hI 2 + − + − − +
hI 3 + − − + − +
hI 4 − + + − + −
hI 5 − + + − − +
hI 6 − + − + − +
Notes: +, applicable; −, not applicable.
Abbreviation: hI, heterogeneity index.
Table 4 rOC curve analysis to determine the predictive 






P-value Two-sided 95% CI
hI 1 0.67 0.050 0.51 0.83
hI 2 0.65 0.074 0.49 0.82
hI 3 0.69 0.030* 0.53 0.85
hI 4 0.73 0.008* 0.58 0.87
hI 5 0.71 0.016* 0.56 0.85
hI 6 0.72 0.009* 0.58 0.87
Note: *Statistically significant.
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
FeV1, forced expiratory volume in 1 second; hI, heterogeneity index; rOC, receiver-
operating characteristic.
Table 5 Critical values of the hI 6 and hI 4 with their respective 
sensitivity and specificity that can be considered to identify 
relevant emphysema heterogeneity with regard to the prediction 











1 0.41 0.66 0.78 9.47 6
2 0.54 0.47 0.89 16.55 4
Notes: The critical value is the value for which the point on the rOC curve has the 
smallest distance to the upper left corner (see Figures 1 and 2). This distance (D) was 
calculated using the following formula: D = √([1 – sensitivity]2 + [1 – specificity]2).
Abbreviations: elVr, endoscopic lung volume reduction; FeV1, forced expiratory 
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Calculating an interlobar emphysema heterogeneity index
of the 50 patients, with a TL reduction of more than 
350 mL.
None of the HIs showed a statistically significant dis-
criminatory capacity between clinically successful and 
unsuccessful treatment assessed with other output parameters 
like RV, SGRQ, or 6MWT. Detailed results of the analyses 
with these output parameters are given in Tables S5–S7.
Discussion
This study indicates that when determining an interlobar 
HI, generally speaking, subtracting the percentages of 
emphysematous lung volume of the lobes in question yields 
better predictive accuracy in ROC analysis than dividing 
them. Furthermore, the results suggest that disregarding the 
right middle lobe, as done in the VENT study by Sciurba 
et al, is reasonable.1 Defining the HI as the emphysema score 
of the TL minus emphysema score of the lung without the 
TL, that is, HI 6, seems to be the most intuitive approach 
with regard to ELVR from our point of view, as the percent-
age of emphysematous lung tissue of the remaining lung is 
compared with that of the lung lobe about to be removed by 
means of atelectasis induction. Indeed, our results confirm 
that this definition yields good predictive accuracy in the 
ROC analysis (AUC =0.72, P=0.009). Interestingly enough, 
Table 6 rOC curve analysis of all patients with a tendency toward 
upper lobe predominant emphysema and upper lobe treatment 
(n=24) to determine the predictive accuracy of the different 
hIs with respect to FeV1 improvement after elVr, assuming an 





P-value Two-sided 95% CI
hI 1 0.77 0.053 0.49 1.00
hI 2 0.76 0.067 0.48 1.00
hI 3 0.88 0.007* 0.73 1.00
hI 4 0.84 0.014* 0.66 1.00
hI 5 0.82 0.023* 0.62 1.00
hI 6 0.87 0.008* 0.72 1.00
Note: MCID as per Jones et al.29 *Statistically significant. 
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
FeV1, forced expiratory volume in one second; hI, heterogeneity index; MCID, 
minimal clinically important difference; rOC, receiver-operating characteristic.
Table 7 rOC curve analysis of all patients with a tendency toward 
lower lobe predominant emphysema and lower lobe treatment 
(n=38) to determine the predictive accuracy of the different 
hIs with respect to FeV1 improvement after elVr, assuming an 





P-value Two sided 95% CI
hI 1 0.62 0.198 0.44 0.80
hI 2 0.62 0.225 0.43 0.80
hI 3 0.62 0.219 0.44 0.80
hI 4 0.63 0.161 0.45 0.81
hI 5 0.64 0.148 0.46 0.82
hI 6 0.65 0.121 0.47 0.82
Note: MCID as per Jones et al.29
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
FeV1, forced expiratory volume in one second; hI, heterogeneity index; MCID, 
minimal clinically important difference; rOC, receiver-operating characteristic.
Figure 2 rOC of all hIs.
Note: *1–2 flag the values closest to the upper left corner.
Abbreviations: hI, heterogeneity index; rOC, receiver-operating characteristic.
1*
2*




















Figure 3 receiver-operating characteristic of all patients with a tendency toward 
upper lobe predominant emphysema and upper lobe treatment (n=24).
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however, this is not the definition that was used in most of the 
major trials published in the literature.1,13,32 Instead, in these 
studies, interlobar emphysema heterogeneity was defined as 
the emphysema score of the TL minus the emphysema score 
of the INTL, disregarding the middle lobe, that is, HI 4 in 
our analysis, which surprisingly enough also yielded the best 
predicative accuracy (AUC =0.73, P=0.008). However, when 
tested with DeLong’s test for two correlated ROC curves, H4 
was only significantly different from HI 2 and HI 5, while 
HI 6 was not significantly different from any of the other 
HIs. The elucidated best definitions of HI should therefore 
be considered as a recommendation only and further studies 
are needed to validate the results.
When clinicians and investigators claim that interlobar 
emphysema heterogeneity has a relevant impact on the 
outcome of lung volume reduction and therefore should be 
taken into consideration when evaluating candidates for this 
treatment, it is only fair to ask what a relevant interlobar 
emphysema heterogeneity is. This study may give an answer 
to that question. When striving for equally good sensitivity 
and specificity, HI 6 performed the best with a threshold 
for identifying relevant emphysema heterogeneity in terms 
of ELVR treatment of ~9.47%. This is a notable result as 
there seems to be a need for such a cutoff value given that 
even very recent studies are still referring to the somewhat 
arbitrary definition of heterogeneous emphysema based on 
visual analysis as known from the National Emphysema 
Treatment Trial published in 2001.11,33,34 It needs to be 
emphasized, though, that while these cutoff values give a 
good first orientation, further studies are needed to validate 
and adjust the exact cutoff value as a patient population of 
50 is still too small for generalization.
Although in accordance with the recently published paper 
from Thomsen et al,12 the fact that none of the HIs showed 
a statistically significant discriminatory capacity between 
clinically successful and unsuccessful treatment assessed 
with the 6MWT, the SGRQ or the RV reduction might also 
be due to the small population size. A bigger study is needed 
to validate this result.
Subgroup analysis of the patient population revealed 
that in patients with predominantly lower lobe emphysema 
and lower lobe treatment, none of the HIs had a statisti-
cally significant discriminatory capacity between clinically 
successful and unsuccessful treatment assessed by FEV
1
 
improvement, whereas in patients with predominantly upper 
lobe emphysema and upper lobe treatment, HI 3, HI 4, HI 5, 
and HI 6 showed a statistically significant and rather good 
discriminatory capacity. This suggests that emphysema 
heterogeneity might indeed only be of importance when 
dealing with upper lobe predominant emphysema and upper 
lobe treatment.
limitations of the study
Our study has several limitations, notably its retrospective 
design and the aforementioned patient population size of 
only 50, which constitutes a major limitation. For this reason, 
this study can only serve as a preliminary study and further 
studies are needed to validate the results.
Furthermore, there are factors other than the emphysema 
heterogeneity that affect the outcome of ELVR such as collat-
eral ventilation, lobar perfusion, and air trapping. However, 
since these other factors affect all differently defined HIs in 
the ROC analysis equally, we are convinced that our results 
remain valid. The fact that there are other factors that affect 
FEV
1
 improvement after ELVR might, in turn, explain the 
overall only fair discriminatory capacity of the HIs. It must 
be emphasized, though, that these other factors mentioned 
previously must also be considered when evaluating a patient 
for lobar lung volume reduction therapy.
Another limitation of the study is the fact that the results 
and conclusion are based on the analysis using FEV
1
 as 
the outcome parameter and somewhat neglected the other 
important output parameters such as change in 6MWT test 
or quality of life.35 Having said that, though, FEV
1
 has been 
recognized as an objective index of airflow obstruction by the 
COPD research community and regulatory agencies.36
Figure 4 receiver-operating characteristic of all patients with a tendency toward 
lower lobe predominant emphysema and lower lobe treatment (n=38).
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Calculating an interlobar emphysema heterogeneity index
Conclusion
Based on the ROC analysis of this study, we recommend 
determining the HI of the lobe in question for ELVR by sub-
tracting the emphysema score of the lung without the TL from 
the emphysema score of the TL, or alternatively, by subtract-
ing the emphysema score of the INTL from the emphysema 
score of the TL, disregarding the middle lobe. The impact of 
interlobar emphysema heterogeneity seems to be of greater 
importance in patients with upper lobe predominant emphy-
sema and upper lobe treatment than in patients with lower 
lobe predominant emphysema and lower lobe treatment.
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Calculating an interlobar emphysema heterogeneity index
Table S1 rOC curve analysis of all patients (n=62) to determine 
the predictive accuracy of the different volume-weighted hIs (hI 
* targeted lobe volume) with respect to FeV1 increased after 





P-value Two-sided 95% CI
hI 1′ 0.64 0.066 0.50 0.78
hI 2′ 0.64 0.056 0.50 0.78
hI 3′ 0.61 0.127 0.47 0.76
hI 4′ 0.66 0.030* 0.52 0.80
hI 5′ 0.66 0.034* 0.52 0.80
hI 6′ 0.66 0.039* 0.51 0.80
Note: MCID as per Jones et al.1
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
FeV1, forced expiratory volume in 1 second; hI, heterogeneity index; MCID, minimal 
clinically important difference; rOC, receiver-operating characteristic.




hI 7 Tar of Tl/Tar of the InTl excluding middle lobe
hI 8 Tar of Tl/Tar of the InTl including middle lobe
hI 9 Tar of Tl/Tar of the whole lung without Tl
Abbreviations: hI, heterogeneity index; InTl, ipsilateral nontargeted lobe; Tar, 
tissue to air ratio; Tl, targeted lobe.
Table S3 rOC curve analysis of all patients (n=62) to determine 
the predictive accuracy of hIs calculated from the Tar with 
respect to FeV1 change after elVr assuming an increase of FeV1 





P-value Two-sided 95% CI
hI 7 0.62 0.104 0.48 0.77
hI 8 0.65 0.041* 0.52 0.79
hI 9 0.67 0.025* 0.53 0.81
Notes: In this rOC analysis, negative outcome is predicted, as the lower the 
Tar the higher the severity of the disease and vice versa (Bandyopadhyay et al2). 
*Statistically significant. MCID as per Jones et al.1
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
FeV1, forced expiratory volume in 1 second; hI, heterogeneity index; rOC, receiver-
operating characteristic; Tar, tissue to air ratio.
Table S4 rOC curve analysis of all patients (n=62) to determine 
the predictive accuracy of the different hIs with respect to FeV1 






P-value Two-sided 95% CI
hI 1 0.64 0.071 0.49 0.78
hI 2 0.64 0.065 0.50 0.78
hI 3 0.66 0.039* 0.51 0.80
hI 4 0.66 0.031* 0.52 0.80
hI 5 0.66 0.035* 0.52 0.80
hI 6 0.68 0.019* 0.54 0.81
Notes: MCID as per Jones et al.1 *Statistically significant.
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
FeV1, forced expiratory volume in 1 second; hI, heterogeneity index; MCID, minimal 
clinically important difference; rOC, receiver-operating characteristic.
Table S5 rOC curve analysis of all patients with available 6MWT 
results (n=44) to determine the predictive accuracy of the different 
hIs with respect to 6MWT improvement after elVr, assuming an 





P-value Two-sided 95% CI
hI 1 0.53 0.750 0.35 0.70
hI 2 0.53 0.697 0.36 0.70
hI 3 0.52 0.850 0.34 0.69
hI 4 0.53 0.768 0.35 0.70
hI 5 0.53 0.777 0.35 0.70
hI 6 0.52 0.832 0.34 0.69
Note: MCID as per Jones et al.1
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
hI, heterogeneity index; MCID, minimal clinically important difference; rOC, 
receiver-operating characteristic; 6MWT, 6-minute walk test.
Table S6 rOC curve analysis of all patients with available sgrQ 
test results (n=47) to determine the predictive accuracy of the 
different hIs with respect to sgrQ improvement after elVr, 





P-value Two-sided 95% CI
hI 1 0.59 0.346 0.41 0.76
hI 2 0.58 0.375 0.40 0.76
hI 3 0.50 0.991 0.32 0.68
hI 4 0.55 0.567 0.37 0.73
hI 5 0.55 0.613 0.37 0.73
hI 6 0.48 0.840 0.30 0.67
Note: MCID as per Jones et al.1
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
hI, heterogeneity index; MCID, minimal clinically important difference; rOC, 
receiver-operating characteristic; sgrQ, st george’s respiratory Questionnaire.
Supplementary materials
Table S7 rOC curve analysis of all patients (n=62) to determine 
the predictive accuracy of the different hIs with respect to rV 






P-value Two-sided 95% CI
hI 1 0.57 0.341 0.43 0.71
hI 2 0.57 0.317 0.43 0.72
hI 3 0.58 0.259 0.44 0.73
hI 4 0.56 0.393 0.42 0.71
hI 5 0.56 0.413 0.42 0.71
hI 6 0.57 0.355 0.42 0.71
Note: MCID as per Jones et al.1
Abbreviations: CI, confidence interval; ELVR, endoscopic lung volume reduction; 
hI, heterogeneity index; MCID, minimal clinically important difference; rOC, 
receiver-operating characteristic; rV, residual volume.
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